Status:
RECRUITING
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
Lead Sponsor:
Stanford University
Collaborating Sponsors:
LUNGevity Foundation
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.
Eligibility Criteria
Inclusion
- Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
- ECOG performance status of 0-2
- Age \> 18 years old
- Ability to understand and the willingness to personally sign the written IRB approved informed consent document
- Estimated life expectancy of 12 weeks or longer
Exclusion
- Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
- Age \< 18 years old
- Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree
- Diagnosis of interstitial pulmonary fibrosis
- Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields
Key Trial Info
Start Date :
October 25 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06080061
Start Date
October 25 2023
End Date
December 1 2026
Last Update
July 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Palo Alto, California, United States, 94305